Glenmark Pharmaceuticals Peer Comparison

NSE: GLENMARK | BSE: 532296

₹2,210.20

₹-16.50 (-0.74%)

As on 19-Oct-2026IST

Market cap

₹62,339 Cr

Revenue (TTM)

₹17,737 Cr

P/E Ratio

34.7

P/B Ratio

5.7

Div. Yield

0.1 %

Edit

	Glenmark Pharmaceuticals	Laurus Labs	Wockhardt	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	62,339	1,11,434	30,978	25,888	26,649
Revenue (₹ Cr)	17,737	7,270	3,564	9,205	1,462
Net Profit (₹ Cr)	1,797.81	1,090.76	414.00	-371.81	387.35
Net Margin (%)	9.86	14.89	11.23	-3.93	26.01
RoE (%)	30.87	21.64	8.38	-3.85	25.18
Price to Earnings	34.67	101.92	75.74	--	69.00
Price-To-Book	5.69	19.76	6.15	3.23	15.45

Income Statement (₹ Cr)

	Glenmark Pharmaceuticals	Laurus Labs	Wockhardt	Piramal Pharma	Acutaas Chemicals
Operating Revenue	17,736.55	7,269.64	3,564.00	9,205.28	1,461.80
Total Income	18,236.50	7,323.34	3,686.00	9,449.59	1,489.25
Total Expenditure	12,939.86	5,235.79	2,792.00	8,195.15	919.25
EBITDA	4,796.69	2,033.85	772.00	1,010.13	542.56
Depreciation	616.73	487.08	226.00	857.51	37.68
EBIT	4,179.96	1,546.77	546.00	152.62	504.88
Interest	204.50	161.45	217.00	342.73	3.77
Other Income	499.94	53.70	122.00	244.31	27.45
Exceptional Items	-1,942.85	0.00	12.00	-216.88	0.00
Profit before Tax	2,532.56	1,439.02	463.00	-162.68	528.56
Provision for Tax	734.75	348.26	49.00	209.13	141.21
Profit after Tax	1,797.81	1,090.76	414.00	-371.81	387.35

	Glenmark Pharmaceuticals	Laurus Labs	Wockhardt	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	10,512.11	5,300.06	4,940.00	8,162.62	1,653.56
Minority Interest	0.10	2.84	-5.00	0.00	-1.13
Non-Current Liabilities	3,019.66	1,444.40	1,712.00	5,044.14	42.40
Current Liabilities	6,376.43	3,635.43	1,622.00	4,758.28	230.82
Total Liabilities	19,906.65	10,511.19	8,578.00	17,723.32	1,983.96

	Glenmark Pharmaceuticals	Laurus Labs	Wockhardt	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	7,567.18	5,220.48	5,343.00	10,211.52	1,026.85
Current Assets	11,299.71	4,829.21	2,606.00	7,191.66	881.27
Total Assets	19,906.65	10,511.19	8,578.00	17,723.32	1,983.96
Total Debt*	0.00	2,397.49	2,125.00	5,495.48	26.49
Net Current Assets	4,923.28	1,193.78	984.00	2,433.38	650.46
Contingent Liabilities	787.81	420.55	768.26	95.72	17.25

	Glenmark Pharmaceuticals	Laurus Labs	Wockhardt	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	3,445.03	1,623.50	390.00	1,652.60	292.17
Cash Flow from Investing Activities	-1,283.23	-1,088.66	-241.00	-826.03	-265.94
Cash from Financing Activities	-2,708.75	-524.72	-54.00	-38.98	4.10
Net Cash Inflow / Outflow	-546.95	10.12	95.00	787.59	30.33

	Glenmark Pharmaceuticals	Laurus Labs	Wockhardt	Piramal Pharma	Acutaas Chemicals
ROCE (%)	20.35	18.20	6.79	1.24	32.42
ROE (%)	30.87	21.64	8.38	-3.85	25.18
ROA (%)	10.00	10.99	4.94	-2.21	21.93
EBIT Margin (%)	23.57	21.28	15.32	1.66	34.54
Net Margin (%)	9.86	14.89	11.23	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Glenmark Pharmaceuticals	Laurus Labs	Wockhardt	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	32.94	22.62	18.37	0.78	40.90
EBIT Growth (%)	126.49	87.41	252.26	-70.53	124.50
Net Profit Growth (%)	138.48	116.73	377.85	-1,383.43	104.15
EPS Growth (%)	174.53	114.66	1,001.33	-484.84	42.32
Book Value Growth (%)	18.53	18.63	13.47	0.33	26.03

	Glenmark Pharmaceuticals	Laurus Labs	Wockhardt	Piramal Pharma	Acutaas Chemicals
Price / Earnings	20.10	101.86	77.74	-82.73	69.00
Price / Book Value	5.69	19.76	6.15	3.23	15.45
Dividend Yield (%)	0.11	0.10	0.00	0.00	0.08
EV/EBITDA	12.75	55.91	42.02	29.73	48.75
Market Cap (₹ Cr)	60,201.30	53,545.31	19,071.62	18,108.89	20,944.75

	Glenmark Pharmaceuticals	Laurus Labs	Wockhardt	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.00	0.12	0.31	0.53	0.02
Short term debt to equity ratio	--	0.28	0.09	0.09	0.02
Current Ratio	1.77	1.33	1.61	1.51	3.82
Quick Ratio	1.23	0.68	1.06	0.87	2.82
Interest Coverage	13.38	9.91	3.13	0.53	141.16

	Glenmark Pharmaceuticals	Laurus Labs	Wockhardt	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	27.98	29.64	16.50	23.44	24.80
Asset Turnover	0.99	0.73	0.43	0.55	0.83
Receivable days	43.78	111.49	58.75	78.20	88.98
Inventory Days	34.05	114.62	75.82	93.30	56.04
Payable days	264.58	155.13	186.21	226.14	99.95
Cash Conversion Cycle	-186.74	70.98	-51.64	-54.64	45.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.